by bureau Peppr | 1 April, 2020 | News
BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer, has selected BioConnection for GMP DP manufacturing. LAVA and BioConnection now...
by bureau Peppr | 18 March, 2020 | News
Oss, The Netherlands, March 18, 2020. BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we are currently in full operation and running on-schedule with regard to our planned productions. Our production department...
by bureau Peppr | 15 April, 2019 | Testimonials
Verona Pharma In early 2016, we at Verona Pharma were looking for a CMO to support the manufacture of clinical trial batches of our lead product RPL554 (ensifentrine), a first-in-class inhaled agent under development for the treatment of respiratory diseases with...
by bureau Peppr | 8 April, 2019 | News
Oss, The Netherlands, April 8, 2019. BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand and to ensure its future company growth. BioConnection, Contract Manufacturing Organization (CMO),...
by bureau Peppr | 13 March, 2019 | News
Oss, The Netherlands, March 13, 2019. BioConnection opens this month, after an intensive engineering and validation program its Flexible GMP area. The area consists of several small scale cleanrooms ranging from class B up to class D. The Flexible GMP area is located...
